ICCM · IceCure Medical Ltd

The filing reports the successful completion of a Special General Meeting of Shareholders following an initial adjournment due to lack of quorum. The adjourned meeting, held later the same day, achieved quorum and resulted in shareholder approval of an agenda item previously disclosed in the Company’s April 22, 2026 Proxy Statement (Exhibit 99.2). While the precise nature of the proposal is not restated here, its inclusion in the Proxy Statement indicates it was material enough to require shareholder action under Israeli corporate law and SEC disclosure rules for foreign private issuers. The timing—convening and completing the vote on the same day—suggests operational responsiveness to procedural requirements. Additionally, the filing serves a procedural function by incorporating itself into multiple active registration statements (Forms F-3 and S-8), thereby updating those filings with current information as of May 11, 2026. No financial, operational, or executive changes are disclosed, and no forward-looking guidance or new agreements are referenced.